Center for Tumor Diagnostics and Therapy, Paracelsus Klinik, Am Natruper Holz 69, Osnabrück, Germany.
Biol Blood Marrow Transplant. 2010 Dec;16(12):1629-48. doi: 10.1016/j.bbmt.2010.02.002. Epub 2010 Feb 7.
Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) are considered the standard of care for many malignancies, including lymphoma, myeloma, and some leukemias. In many cases, mobilized peripheral blood has become the preferred source of hematopoietic stem cells. The efficacy of different mobilization regimens and transplantation outcomes based on cell doses has been well studied; however, the characteristics of the stem cell graft may be of equal importance with respect to patient outcomes following autologous or allogeneic HSCT. This review summarizes available preclinical and clinical data for bone marrow and mobilized peripheral blood HSCT characteristics, defined as the cell types found in the graft as well as their gene expression profiles. It also explores how graft characteristics can affect bone marrow homing, engraftment, immune reconstitution, and other posttransplantation outcomes in both the allogeneic and autologous HSCT settings.
自体和同种异体造血干细胞移植（HSCT）被认为是许多恶性肿瘤的标准治疗方法，包括淋巴瘤、骨髓瘤和一些白血病。在许多情况下，动员的外周血已成为造血干细胞的首选来源。不同动员方案的疗效和基于细胞剂量的移植结果已经得到了很好的研究；然而，对于自体或同种异体 HSCT 后的患者结果而言，干细胞移植物的特征可能与细胞剂量具有同等重要性。本综述总结了骨髓和动员外周血 HSCT 特征的现有临床前和临床数据，这些特征定义为移植物中发现的细胞类型及其基因表达谱。它还探讨了移植物特征如何影响同种异体和自体 HSCT 环境中的骨髓归巢、植入、免疫重建和其他移植后结果。
